Biogen said it will end development and commercialization of its controversial Alzheimer’s drug Aduhelm, which was approved against outside experts’ advice in mid-2021 and caused congressional inquiries and broader market pushback on pricing and efficacy.
While the company didn’t take the official step of pulling the drug from the market, this essentially discontinues the drug. Biogen said in a statement that it will hand rights for Aduhelm back to original owner Neurimmune, and took a one-time charge of $60 million in the fourth quarter.
By walking away from Aduhelm, Biogen said it will free up resources for Leqembi, its follow-up anti-amyloid treatment developed with Eisai, and will speed up work on other modalities, including an antisense oligonucleotide targeting tau (BIIB080) and an oral small molecule inhibitor of tau aggregation (BIIB113).
“Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks